Skip to main content
Clinical Trials/NCT06637059
NCT06637059
Completed
Not Applicable

Construction of an Artificially Intelligent Model for Accurate Detection of HCC by Integrating Clinical, Radiological, and Peripheral Immunological Features

Zhejiang University0 sites1,092 target enrollmentJanuary 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hepatocellular Carcinoma (HCC)
Sponsor
Zhejiang University
Enrollment
1092
Primary Endpoint
Diagnosis of liver disease through CT imaging
Status
Completed
Last Updated
last year

Overview

Brief Summary

Purpose: Integrating comprehensive information on hepatocellular carcinoma (HCC) is essential to improve its early detection. The investigators aimed to develop a model with multi-modal features (MMF) using artificial intelligence (AI) approaches to enhance the performance of HCC detection.

Experimental Design: A total of 1,092 participants were enrolled from 16 centers. These participants were allocated into the training, internal validation, and external validation cohorts. Peripheral blood specimens were collected prospectively and subjected to mass cytometry analysis. Clinical and radiological data were obtained from electrical medical records. Various AI methods were employed to identify pertinent features and construct single-modal models with optimal performance. The XGBoost algorithm was utilized to amalgamate these models, integrating multi-modal information and facilitating the development of a fusion model. Model evaluation and interpretability were demonstrated using the SHapley Additive exPlanations method.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
October 1, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Zhejiang University
Responsible Party
Principal Investigator
Principal Investigator

TingBo Liang

Professor

Zhejiang University

Eligibility Criteria

Inclusion Criteria

  • Benign liver diseases, including but not limited to, hemangiomas, hepatic cysts, focal nodular hyperplasia, and cirrhosis

Exclusion Criteria

  • Participants who had undergone previous treatment for HCC or benign liver diseases,
  • had taken medications affecting the hematological system within 2 weeks
  • those who had received a blood transfusion within 6 months

Outcomes

Primary Outcomes

Diagnosis of liver disease through CT imaging

Time Frame: 1 month

Similar Trials